Literature DB >> 26882125

Surgical Treatment of Paget Disease of the Vulva: Prognostic Significance of Stromal Invasion and Surgical Margin Status.

Francesco Sopracordevole1, Jacopo Di Giuseppe, Giovanni De Piero, Vincenzo Canzonieri, Monica Buttignol, Giorgio Giorda, Andrea Ciavattini.   

Abstract

OBJECTIVE: The aim of the study was to evaluate the risk of recurrence according to the surgical margin status and the presence of invasion or of superficially invasive carcinoma in patients with extramammary Paget disease (EMPD) of the vulva, who underwent elective surgical treatment.
MATERIALS AND METHODS: We performed a retrospective analysis of 27 patients with first diagnosis of extramammary Paget disease of the vulva, who underwent primary and elective surgical treatment from January 1989 to December 2014. A p value of less than .05 was considered statistically significant. Multivariable logistic regression was performed to adjust for confounding factors.
RESULTS: We observed invasive disease in 11 cases, with microinvasion in 8 of them. A positive surgical margin was found in 10 patients. During a median follow-up period of 79.5 months, 8 patients (29.6%) showed a first recurrence after a median (range) time of 4.9 (2.3-7.1) years. No significant differences were observed between patients with recurrence and patients without recurrence with respect to age, number of vulvar sectors involved, bilaterality and multifocality, presence of invasion or microinvasion, and surgical margin status. However, during the follow-up period, the presence of invasion was higher (67% vs 41%) in patients with recurrence compared with patients without recurrence.
CONCLUSIONS: The rate of recurrence of the disease after therapy is high. Patients should be subjected to a close and long-term follow-up to identify those who must undergo further treatment, especially if they presented with an invasive or even microinvasive disease. A free margin of no greater than 1 to 2 cm might be the most appropriate surgical choice.

Entities:  

Mesh:

Year:  2016        PMID: 26882125     DOI: 10.1097/LGT.0000000000000191

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  7 in total

Review 1.  Surgical Treatment for Extramammary Paget's Disease.

Authors:  Uwe Wollina; Alberto Goldman; Andrzej Bieneck; Mohamed Badawy Abdel-Naser; Sven Petersen
Journal:  Curr Treat Options Oncol       Date:  2018-05-03

Review 2.  Current Management and Treatment of Extramammary Paget's Disease.

Authors:  Hiroki Hashimoto; Takamichi Ito
Journal:  Curr Treat Options Oncol       Date:  2022-04-04

3.  Extramammary Paget disease of the vulva: immunohistochemical analysis of neoangiogenesis and epithelial-mesenchymal transition markers expression.

Authors:  Lara Alessandrini; Nicolò Clemente; Tiziana Perin; Giorgio Giorda; Vincenzo Canzonieri; Francesco Sopracordevole
Journal:  Diagn Pathol       Date:  2018-01-03       Impact factor: 2.644

4.  Mucosal Invasion, but Not Incomplete Excision, Has Negative Impact on Long-Term Survival in Patients With Extramammary Paget's Disease.

Authors:  Hiroki Hashimoto; Yumiko Kaku-Ito; Masutaka Furue; Takamichi Ito
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

5.  CDK4: A Novel Therapeutic Target for Extramammary Paget's Disease.

Authors:  Hiroki Hashimoto; Yumiko Kaku-Ito; Yoshinao Oda; Takamichi Ito
Journal:  Front Oncol       Date:  2021-07-29       Impact factor: 6.244

6.  Prognostic value of treatment options for extramammary Paget's disease: a SEER database analysis.

Authors:  Xiaobo Ma; Yongfeng Li
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

7.  Development and Validation of an Artificial Intelligence-Based Image Classification Method for Pathological Diagnosis in Patients With Extramammary Paget's Disease.

Authors:  Hao Wu; Huyan Chen; Xuchao Wang; Liheng Yu; Zekuan Yu; Zhijie Shi; Jinhua Xu; Biqin Dong; Shujin Zhu
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.